Impact of regorafenib in the clinical practice and identification of second-line treatment orphan patients

MLA

Ernest Belmonte, et al. “Impact of Regorafenib in the Clinical Practice and Identification of Second-Line Treatment Orphan Patients.” Journal of Hepatology, vol. 68, Apr. 2018, pp. S205–06. EBSCOhost, https://doi.org/10.1016/s0168-8278(18)30623-8.

APA

Ernest Belmonte, Jordi Bruix, Anna Darnell, M. Reig, Neus Llarch, Marco Sanduzzi Zamparelli, Alejandro Forner, Álvaro Díaz-González, L.G. Da Fonseca, Josep Corominas, Loreto Boix, Gemma Iserte, C. Ayuso, & Victor Sapena. (2018). Impact of regorafenib in the clinical practice and identification of second-line treatment orphan patients. Journal of Hepatology, 68, S205–S206. https://doi.org/10.1016/s0168-8278(18)30623-8

Chicago

Ernest Belmonte, Jordi Bruix, Anna Darnell, M. Reig, Neus Llarch, Marco Sanduzzi Zamparelli, Alejandro Forner, et al. 2018. “Impact of Regorafenib in the Clinical Practice and Identification of Second-Line Treatment Orphan Patients.” Journal of Hepatology 68 (April): S205–6. doi:10.1016/s0168-8278(18)30623-8.